clinical trial · NCT04556617
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic Castration-resistant Prostate CancerPLX2853 20 mgOlaparibAbiraterone acetatePrednisonePLX2853 40 mgPLX2853 80 mg
brief summary
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
started
Sep 21, 2020
primary completion
May 24, 2022
completion
May 24, 2022
last updated
Apr 8, 2025
official title
A Multicenter, Open-Label, Parallel, Phase 1b/2a Study of PLX2853 in Combination With Abiraterone Acetate and Prednisone and Phase 1b/2a Study of PLX2853 in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol